Clinical and morphological features in patients with advanced endometrial cancer treated with immunotargeting therapy
Background. Endometrial cancer (EC) is one of the most significant oncogynecological problems. The main mortality cause in this disease, as in the case of other malignant neoplasms, is the tumor progression. The presence of mutations associated with mismatch repair-deficient is of great prognostic i...
Saved in:
Main Authors: | L. A. Kolomiets, M. N. Stakheeva, O. N. Churuksaeva, A. B. Villert, A. L. Chernyshova, V. G. Sisakyan, I. Yu. Lots, N. M. Chernorubashkina, V. N. Zhurman, A. A. Grechkina, E. N. Aleksandrova, N. E. Musaeva, O. V. Diduk, N. A. Bulygina, D. A. Pyatina, I. L. Obraz, A. V. Krechetova, M. A. Danilova, M. A. Khodzhakhova, A. A. Malsteva, N. A. Ermak |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2023-08-01
|
Series: | Опухоли женской репродуктивной системы |
Subjects: | |
Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/1095 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tumor microenvironment parameters as a predictor of the duration of clinical effectiveness of immunotargeted therapy in advanced or metastatic endometrial cancer: A pilot multicenter observational study
by: A. A. Maltseva, et al.
Published: (2024-05-01) -
The long-term clinical efficacy and safety of lenvatinib plus pembrolizumab in endometrial cancer: data from routine clinical practice in Russia
by: A. E. Protasova, et al.
Published: (2024-11-01) -
Efficient sequence of therapy for advanced and metastatic endometrial cancer
by: A. A. Rumyantsev
Published: (2022-09-01) -
Combination of pembrolizumab and lenvatinib in second-line therapy for MSS/pMMR advanced endometrial cancer: literature review and a case report
by: A. D. Darenskaya, et al.
Published: (2024-01-01) -
Immunotargeting of Melanoma
by: Mackiewicz, Jacek, et al.
Published: (2011)